Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 2 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2022 Filed Jun 7, 2022 21:00 UTC |
Attar Eyal C.Director · SVP, Chief Medical Officer
|
Tax withholdingCommon Stock | 32,667 | $0.81 | $26,296.94 |
DisclosureSEC source: 0001104659-22-068995 · tm2217848-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,233 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:30 UTC |
SCHADE CHRISTIAN SDirector · Chairman & CEO
|
PurchaseCommon Stock | 37,500 | $0.64 | $24,123.75 |
DisclosureSEC source: 0001104659-22-062916 · tm2216022-1_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,616 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:31 UTC |
Seizinger Bernd R.Director
|
PurchaseCommon Stock | 50,000 | $0.71 | $35,500.00 |
DisclosureSEC source: 0001104659-22-062920 · tm2216022d2_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,580 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC |
SCHADE CHRISTIAN SDirector · Chairman & CEO
|
GrantStock Option (right to Buy) · Derivative | 427,700 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033393 · tm229119-5_4seq1.xml · derivative · entry 9 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,700 Underlying: Common Stock · 427,700 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC |
SCHADE CHRISTIAN SDirector · Chairman & CEO
|
GrantCommon Stock | 100,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033393 · tm229119-5_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,116 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 33,366 shares on March 10, 2023, (ii) 33,367 shares on March 10, 2024 and (iii) 33,367 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC |
Attar Eyal C.Director · SVP, Chief Medical Officer
|
GrantStock Option (right to Buy) · Derivative | 185,900 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033390 · tm229119-2_4seq1.xml · derivative · entry 4 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,900 Underlying: Common Stock · 185,900 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC |
Attar Eyal C.Director · SVP, Chief Medical Officer
|
GrantCommon Stock | 42,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033390 · tm229119-2_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,900 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 17:02 UTC |
Coiante Scott MDirector · SVP, Chief Financial Officer
|
GrantStock Option (right to Buy) · Derivative | 185,900 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033391 · tm229119-3_4seq1.xml · derivative · entry 2 Coiante Scott M · CIK 0001608536 · Director · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,900 Underlying: Common Stock · 185,900 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 17:02 UTC |
Coiante Scott MDirector · SVP, Chief Financial Officer
|
GrantCommon Stock | 42,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033391 · tm229119-3_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · Director · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,549 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC |
Korbel Gregory AlanDirector · SVP, Chief Business Officer
|
GrantStock Option (right to Buy) · Derivative | 72,600 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,600 Underlying: Common Stock · 72,600 shares Expires 2032-03-10 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC |
Korbel Gregory AlanDirector · SVP, Chief Business Officer
|
Tax withholdingCommon Stock | 1,989 | $1.82 | $3,619.98 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,852 F2 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC |
Korbel Gregory AlanDirector · SVP, Chief Business Officer
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,841 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
GrantStock Option (right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033389 · tm229119-1_4seq1.xml · derivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
GrantCommon Stock | 24,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033389 · tm229119-1_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,700 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:01 UTC |
Attar Eyal C.SVP, Chief Medical Officer
|
SaleCommon Stock | 36,000 | $1.73 | $62,280.00 |
DisclosureSEC source: 0001104659-22-028757 · tm227953-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.77 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:02 UTC |
SCHADE CHRISTIAN SDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 21,644 | $1.74 | $37,660.56 |
DisclosureSEC source: 0001104659-22-028767 · tm227953-4_4seq1.xml · nonDerivative · entry 1 SCHADE CHRISTIAN S · CIK 0001214496 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,016 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 55,166 restricted stock units. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 17:01 UTC |
Coiante Scott MSVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 14,817 | $1.74 | $25,781.58 |
DisclosureSEC source: 0001104659-22-028760 · tm227953-2_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,649 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 32,167 restricted stock units. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:02 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Tax withholdingCommon Stock | 1,326 | $1.74 | $2,307.24 |
DisclosureSEC source: 0001104659-22-028761 · tm227953-3_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 3,333 restricted stock units. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 27,500 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 26, 2017 and is fully exercisable. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
SaleCommon Stock | 27,500 | $3.96 | $108,900.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.12 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 2,255 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · derivative · entry 4 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,835 Underlying: Common Stock · 2,255 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on February 26, 2017 and is fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 25,245 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,245 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
SaleCommon Stock | 27,500 | $5.00 | $137,500.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $5.09 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · derivative · entry 3 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,587 Underlying: Common Stock · 50,000 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
SaleCommon Stock | 50,000 | $4.89 | $244,500.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · nonDerivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.05 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 50,000 | $0.92 | $46,000.00 |
DisclosureSEC source: 0001104659-21-123186 · tm2129205-2_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 Underlying: Common Stock · 27,500 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
SaleCommon Stock | 27,500 | $4.89 | $134,475.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · derivative · entry 4 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,745 Underlying: Common Stock · 27,500 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
SaleCommon Stock | 27,500 | $4.97 | $136,675.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.54 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC |
Korbel Gregory AlanSVP, Chief Business Officer
|
SaleCommon Stock | 5,460 | $4.98 | $27,190.80 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.76 to $5.48 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · derivative · entry 3 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,587 Underlying: Common Stock · 25,000 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
SaleCommon Stock | 25,000 | $4.97 | $124,250.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · nonDerivative · entry 2 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.57 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:00 UTC |
Abrahmsen Lars B.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 25,000 | $0.92 | $23,000.00 |
DisclosureSEC source: 0001104659-21-118360 · tm2127534-3_4seq1.xml · nonDerivative · entry 1 Abrahmsen Lars B. · CIK 0001789039 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:29 UTC |
Attar Eyal C.SVP, Chief Medical Officer
|
SaleCommon Stock | 15,968 | $4.68 | $74,730.24 |
DisclosureSEC source: 0001104659-21-117446 · tm2127534-2_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.85 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:01 UTC |
Korbel Gregory AlanChief Business Officer
|
Tax withholdingCommon Stock | 1,724 | $4.59 | $7,913.16 |
DisclosureSEC source: 0001104659-21-115547 · tm2127534-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,627 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 17:01 UTC |
Coiante Scott MSVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 7,534 | $3.98 | $29,985.32 |
DisclosureSEC source: 0001104659-21-110596 · tm2126037-2_4seq1.xml · nonDerivative · entry 1 Coiante Scott M · CIK 0001608536 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,466 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 21,166 restricted stock units. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 21:02 UTC |
Korbel Gregory AlanChief Business Officer
|
Tax withholdingCommon Stock | 1,149 | $3.98 | $4,573.02 |
DisclosureSEC source: 0001104659-21-110599 · tm2126037-3_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 3,333 restricted stock units. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 21:00 UTC |
Attar Eyal C.SVP, Chief Medical Officer
|
Tax withholdingCommon Stock | 9,032 | $3.98 | $35,947.36 |
DisclosureSEC source: 0001104659-21-110595 · tm2126037-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,968 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 18:58 UTC |
Namouni FouadDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012871 · doc1.xml · derivative · entry 2 Namouni Fouad · CIK 0001815851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 18:58 UTC |
Namouni FouadDirector
|
GrantCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012871 · doc1.xml · nonDerivative · entry 1 Namouni Fouad · CIK 0001815851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:09 UTC |
HENNEMAN JOHN B IIIDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012875 · doc1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:09 UTC |
HENNEMAN JOHN B IIIDirector
|
GrantCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012875 · doc1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:02 UTC |
Peters RichardDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012873 · doc1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:02 UTC |
Peters RichardDirector
|
GrantCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012873 · doc1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:07 UTC |
Kelly Michael AaronDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012874 · doc1.xml · derivative · entry 2 Kelly Michael Aaron · CIK 0001769668 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.